IC
VRDN icon

Ikarian Capital’s Viridian Therapeutics VRDN Stock Holding History

Ikarian Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,789
Closed -$3.63M – 172
2024
Q2 		$3.63M Sell
2,789
-176,111
-98% -$2.44M 0.63% 38
2024
Q1 		$3.13M Buy
+178,900
New +$3.47M 0.34% 68

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ikarian Capital's VRDN Position: Q2 2026 in Review

Ikarian Capital opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 425,000 shares worth $7.81M. The stake represents 0.84% of the portfolio and ranks #34 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in VRDN as recently as Q3 2025.

Ikarian Capital first reported a position in VRDN in Q3 2024 and has held it in 6 quarters since. The position peaked at $11.4M in Q3 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Ikarian Capital held 425,000 shares of Viridian Therapeutics worth $7.81M as of Q2 2026.
  • Viridian Therapeutics was a new Ikarian Capital position in Q2 2026.
  • Viridian Therapeutics made up 0.84% of Ikarian Capital's portfolio in Q2 2026, its #34 holding.
  • Ikarian Capital first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Ikarian Capital's Viridian Therapeutics position peaked at $11.4M in Q3 2024.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.